Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: Allovectin-7, Vical.

Evanthia Galanis1

  • 1Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA. galanis.evanthia@mayo.edu

Current Opinion in Molecular Therapeutics
|March 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

2025 Advancing Cell and Gene Therapies for Cancer post-meeting report.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

HSR26-206: The Future of Oncology Research: Replacing Case Report Forms With mCODE-Aligned Electronic Health Record Data for Clinical Trial Data Curation (Alliance).

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, <i>IDH</i>-wildtype.

Neuro-oncology advances·2026
Same author

HSR26-206: The Future of Oncology Research: Replacing Case Report Forms With mCODE-Aligned Electronic Health Record Data for Clinical Trial Data Curation (Alliance).

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Allovectin-7, a gene therapy for cancers like melanoma, shows promising response rates and stable disease in refractory patients. This immunotherapy approach is well-tolerated, with ongoing trials exploring higher doses and combination therapies.

Area of Science:

  • Oncology
  • Gene Therapy
  • Immunotherapy

Background:

  • Allovectin-7 is a gene transfer product combining human leukocyte antigen HLA-B7 and beta2-microglobulin genes.
  • It is being developed as an immunotherapy for various malignancies, particularly melanoma and head and neck cancers.

Purpose of the Study:

  • To evaluate the efficacy and safety of Allovectin-7 in patients with refractory metastatic melanoma.
  • To assess the activity of Allovectin-7 in advanced refractory head and neck squamous cell carcinoma.

Main Methods:

  • Phase II trials involving patients with refractory metastatic melanoma and advanced head and neck cancer.
  • Administration of Allovectin-7 via gene transfer, with ongoing evaluations of higher doses and multiple tumor injections.

Related Experiment Videos

Main Results:

  • In metastatic melanoma, systemic response rates of 11% (intent-to-treat) and 15% (evaluable) were observed, with stable disease in 19.2% and 25.9%, respectively.
  • In head and neck cancer, 10% achieved partial response and 23% had stable disease after one cycle.
  • Treatment was well-tolerated, with mild injection site and flu-like symptoms.

Conclusions:

  • Allovectin-7 demonstrates promising efficacy and a favorable safety profile in treating refractory metastatic melanoma and head and neck cancers.
  • Further trials, including Phase III studies and adjuvant treatment evaluations, are planned to further establish its therapeutic potential.